Product
Rapamune
Aliases
Rapamune® (Sirolimus)
Name
Rapamune
INN Name
SIROLIMUS
FDA Approved
Yes
4 clinical trials
1 organization
3 indications
1 document
Indication
Kidney TransplantIndication
Muscle AtrophyIndication
SarcopeniaClinical trial
An Open-label, Concentration-controlled, Randomized, 6-month Study of 'Standard Dose' Tacrolimus + Sirolimus + Corticosteroids Compared to 'Reduced-dose' Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft RecipientsStatus: Completed
Clinical trial
A Comparative, Open-label Study to Evaluate Graft Function in de Novo Renal Allograft Recipients Treated With Either a 'Reduced Dose' or a 'Standard Dose' of Cyclosporine in Combination With Sirolimus and CorticosteroidsStatus: Completed
Clinical trial
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle.Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Phase 4 Study: Comparison of Myfortic and Early Rapamycin Conversion vs. Low-Dose Tacrolimus in Preventing Acute Rejection and Chronic Allograft Fibrosis: A Protocol Biopsy Directed ApproachStatus: Completed, Estimated PCD: 2011-11-11
Document
DailyMed Label: Rapamune